Tizanidine Hydrochloride Capsule, Gelatin Coated
Product Images NDC 60505-2648

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 60505-2648). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2mg-150btl (2mg 150btl)

Tizanidine Hydrochloride Capsules 2 mg gelatin coated oral capsules packaging label by Apotex Corp. The label states each capsule contains 2 mg tizanidine hydrochloride USP, with a package size of 150 capsules. The label includes storage instructions, a warning that these capsules are not interchangeable with tablets or Zanaflex tablets, and manufacturing information for Apotex Inc. in Toronto, Ontario, and Apotex Corp. in Florida. The NDC displayed is 60505-2648-7.*

FDA Label Image

4mg-150btl (4mg 150btl)

Tizanidine Hydrochloride Capsules 4 mg gelatin coated oral capsules label from Apotex Corp. The label states the product contains 150 capsules with each capsule containing 4 mg of tizanidine base. It includes storage instructions, dosage notes, manufacturer information, NDC 60505-2649-7, and a warning that these capsules are not interchangeable with tizanidine tablets or Zanaflex tablets.*

FDA Label Image

6mg-150btl (6mg 150btl)

Label for Tizanidine Hydrochloride Capsules 6 mg by Apotex Corp. Contains 150 gelatin-coated capsules. The label includes dosage information, storage instructions, a warning that the capsules are not interchangeable with tablets, and manufacturer details with a barcode and NDC 60505-2650-7.*

FDA Label Image

Chemicalstructure (Chemical Structure)

Chemical structure of Tizanidine Hydrochloride, showing the arrangement of chlorine, nitrogen, sulfur, and hydrogen atoms within the molecular framework.*

FDA Label Image

Figure2 (Figure 2)

A line graph showing improvement in Ashworth Score after dosing with 8 mg tizanidine, 16 mg tizanidine, and placebo over a 6-hour period. The y-axis measures improvement, and the x-axis shows hours post-dose, highlighting greater improvement with higher tizanidine doses compared to placebo.*

FDA Label Image

Figure3 (Figure 3)

A line graph showing improvement in Ashworth Score over three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). Two groups are compared: tizanidine (mean dose 28.8 mg) and placebo, with error bars illustrating variability. The tizanidine group shows greater improvement (negative scores) at all points compared to placebo.*

FDA Label Image

Figure1 (Figure1)

A pharmacokinetic plasma concentration-time graph showing Tizanidine levels in ng/mL over 24 hours post dosing. The plot compares 4 mg doses of Tizanidine tablets and capsules with and without food intake, illustrating concentration peaks and declines for each condition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.